BIOMX
BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.
BIOMX
Industry:
Biotechnology Health Care Therapeutics
Founded:
2015-01-01
Address:
Ness Ziona, HaMerkaz, Israel
Country:
Israel
Website Url:
http://www.biomx.com
Total Employee:
11+
Status:
Active
Contact:
+97289553100
Email Addresses:
[email protected]
Total Funding:
74 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-12-19 | RondinX | RondinX acquired by BIOMx | N/A |
Investors List
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Post-IPO Equity - BIOMx
8VC
8VC investment in Series B - BIOMx
Handok
Handok investment in Series B - BIOMx
SBI Japan-Israel Innovation Fund
SBI Japan-Israel Innovation Fund investment in Series B - BIOMx
Chong Kun Dang Pharmaceutical Corp.
Chong Kun Dang Pharmaceutical Corp. investment in Series B - BIOMx
Johnson & Johnson Innovation
Johnson & Johnson Innovation investment in Series B - BIOMx
Takeda Ventures
Takeda Ventures investment in Series B - BIOMx
OrbiMed
OrbiMed investment in Series B - BIOMx
Seventure Partners
Seventure Partners investment in Series B - BIOMx
KB Investment
KB Investment investment in Series B - BIOMx
Official Site Inspections
http://www.biomx.com Semrush global rank: 3.59 M Semrush visits lastest month: 4 K
- Host name: 104.21.37.10
- IP address: 104.21.37.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BIOMx"
About - Biomx
Marina Wolfson, Chief Financial Officer, joined BiomX in December 2019, bringing extensive experience from large pharmaceutical and high-tech companies, as well as venture capital …See details»
BiomX | Phage therapy
Press Releases May 08, 2025 BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025. Events May 15, 2025 2:00 pm EDT First Quarter 2025 Financial Results Conference Call. View All. …See details»
BIOMx - Crunchbase Company Profile & Funding
BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and …See details»
Company Information :: BiomX, Inc. (PHGE)
Company. BiomX, Inc. 708 Quince Orchard Rd Suite 205 Gaithersburg, MD 20878 USA [email protected]See details»
Revolutionizing the Treatment of Serious Infections Through
Complementary approaches taken by BiomX for phage treatment • Enables rapid entry into clinical proof of concept, prior to fixed cocktail design • Could be applied to polymicrobial …See details»
Board of Directors :: BiomX, Inc. (PHGE)
Prior to his role in BiomX, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative …See details»
BIOMx - Funding, Financials, Valuation & Investors - Crunchbase
BIOMx is registered under the ticker NYSEMKT:PHGE . BIOMx is funded by 16 investors. Cystic Fibrosis Foundation and Deerfield Management are the most recent investors. BIOMx has …See details»
BiomX - Org Chart, Teams, Culture & Jobs - The Org
BiomX is developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, …See details»
BiomX - Overview, News & Similar companies | ZoomInfo.com
Who is BiomX. BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic …See details»
BiomX Company Profile - Office Locations, Competitors, Revenue …
BiomX has 5 employees at their 1 location and $56 m in total funding,. See insights on BiomX including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
BiomX | Deerfield
BiomX | DeerfieldSee details»
BiomX Company Profile, Investors, & Funding | Lucidity Insights
BiomX is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis …See details»
BiomX - VentureRadar
BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as …See details»
Investor Relations :: BiomX, Inc. (PHGE)
Mar 31, 2025 Company. BiomX, Inc. 708 Quince Orchard Rd Suite 205 Gaithersburg, MD 20878 USA [email protected]See details»
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 …
1 day ago In March 2025, BiomX announced positive topline results from the Phase 2 trial in which BX211 was demonstrated to be safe and well-tolerated and patients receiving BX211 …See details»
BiomX Reports First Quarter 2025 Financial Results and Provides ...
5 days ago NESS ZIONA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel …See details»
Careers - Biomx
WHAT DOES IT MEAN TO BE A PART OF BIOMX? We share a sense of purpose across the organization, with every role. We cultivate and build upon industry-leading, global expertise. …See details»
BiomX Inc. to Present Positive Phase 2 Results for BX211 at
1 day ago BiomX will present Phase 2 trial results for BX211 targeting diabetic foot infections at Biomed Israel 2025. Quiver AI Summary. BiomX Inc., a clinical-stage company specializing in …See details»
Our Pipeline - Biomx
We have entered into two collaborations with Boehringer Ingelheim. Our first collaboration with Boehringer Ingelheim was announced in September 2020 (see press release) utilizes the …See details»
BiomX Announces Entry into Merger Agreement with Adaptive …
Mar 6, 2024 About BX004 BiomX is developing BX004, a fixed multi-phage cocktail, for the treatment of CF patients with chronic pulmonary infections caused by P. aeruginosa, a main …See details»